Industry coverage tracks the money around peptides: Eli Lilly and Novo Nordisk earnings, pipeline shifts, M&A, IPOs, peptide CDMO capacity, and the telehealth and pharmacy economy that GLP-1s built.
The two stories that keep moving the most market cap: how fast oral GLP-1s reach approval (orforglipron, oral semaglutide, oral wegovy, danuglipron's exit), and what happens to the compounded-peptide channel as the FDA tightens. Hims, Ro, LifeMD, GoodRx, and Amazon Pharmacy have all rerouted distribution in the past year. Behind them, contract manufacturers like Bachem, PolyPeptide, and BASF have been the bottleneck no one talked about until they were.
Stories here name the company, the deal, and the dollars. Earnings, partnership, regulatory hit — whatever moved the share price gets covered.
Osivax (clinical-stage French biopharmaceutical) and GC Biopharma (South Korean vaccine maker, KRX: 006280) announced Thursday August 27, 2026 a long-term collaboration to develop and commercialize a next-generation seasonal influenza vaccine candidate combining OVX836 (Osivax's broad-spectrum influenza A vaccine targeting the highly conserved nucleoprotein NP, in Phase 2 development) with GC FLU (GC Biopharma's marketed inactivated influenza vaccine). Osivax receives a non-exclusive sublicensable global license (excluding Japan and Korea) to use GC FLU in combination with OVX836 and will lead global development and commercialization outside South Korea; GC Biopharma retains exclusive Korean rights, receives royalties, and ensures long-term supply of GC FLU. Financial terms were not disclosed. The NP-targeted broad-spectrum approach positions the combination to address the annual antigenic-drift problem that has kept seasonal influenza vaccine efficacy in the 30-60% range and drives interest in peptide- and protein-based broadly conserved epitope vaccines.
ProFound Therapeutics (Flagship Pioneering company, Cambridge, Massachusetts) announced Thursday August 27, 2026 an investment commitment of up to $35 million from the Bill and Melinda Gates Foundation for preeclampsia and eclampsia drug target and biomarker discovery. Structure: $20 million upfront plus $15 million tied to experimental milestones. ProFound will apply its ProFoundry platform (a proteomics-scale discovery engine that identifies previously undetected proteins from tissue and serum) and its agentic AI tooling to placental tissue and serum samples from women with the conditions in search of first-in-class protein drug targets and biomarkers. Preeclampsia affects roughly 5-8% of pregnancies globally and remains a leading cause of maternal and fetal morbidity and mortality; there are currently no approved disease-modifying drugs. The Gates commitment continues the foundation's pattern of directing capital toward maternal health gaps that private capital has under-served.
BioXcel Therapeutics (NASDAQ: BTAI) filed for Chapter 11 bankruptcy protection Thursday August 27, 2026 after telling investors it lacked cash to fund operations through the end of August despite securing a bridge loan earlier the same week. Teva Pharmaceutical Industries (NYSE: TEVA) signed a stalking-horse asset sale agreement Friday August 28, 2026 to acquire BioXcel's lead neuroscience asset for $57.5 million upfront plus up to $67.5 million in milestone payments through a court-supervised auction. The lead asset is a novel dexmedetomidine sublingual film under FDA review for at-home use for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults, with a PDUFA target action date of November 14, 2026. The stalking-horse bid sets the floor price for competing bidders. Teva positioned the acquisition as consistent with its 'Pivot to Growth' strategy and disciplined business development approach.
Alongside the FDA approval announcement Thursday August 27, 2026, Roivant Sciences (NASDAQ: ROIV) filed an 8-K disclosure and hosted a conference call Friday August 28, 2026 confirming that Priovant Therapeutics has fielded a dermatology-and-rheumatology-focused sales force, contracted with major specialty pharmacy distributors, and secured initial payer coverage sufficient to begin U.S. commercial launch on August 28. Priovant is a Pfizer-Roivant joint venture (Roivant 75%, Pfizer 25%) that was created in 2022 specifically to advance brepocitinib in dermatomyositis, cutaneous lupus, and non-infectious uveitis. Beyond Lisraya, Priovant's brepocitinib program continues in Phase 3 for cutaneous lupus (VALIANT) with topline data expected in H1 2027 and in Phase 2 for non-infectious uveitis. The launch is a signal event for the Roivant 'Vant' model, in which spin-out subsidiaries develop and commercialize discrete assets while remaining consolidated within the parent. Not a peptide; included because the JAK/TYK2 inhibitor category continues to displace older peptide-based immunomodulation approaches in autoimmune disease.
Biohaven Ltd. (NYSE: BHVN) on Wednesday August 26, 2026 signed an exclusive, royalty-bearing worldwide license with SK Biopharmaceuticals for its Kv7 ion channel platform led by opakalim (BHV-7000, a selective Kv7.2/7.3 potassium channel activator in Phase 2/3 for focal epilepsy). Deal terms: upfront and milestone payments up to $795 million plus tiered royalties from the mid-teens to low twenties on U.S. net sales of opakalim, with SK Biopharmaceuticals responsible for development, regulatory filings, and commercialization in the United States, Europe, and Japan. The Phase 2/3 RISE3 trial for opakalim is ongoing with topline data expected in H2 2026. Biohaven shares jumped roughly 13% on the announcement. Opakalim is a small-molecule ion channel activator and not a peptide; the deal is included here because it is one of the largest neuroscience licensing transactions of the year and continues the pattern of Korean pharma partners (SK, Hanmi, Yuhan) becoming serious in-licensing counterparties for U.S. biotechs seeking non-dilutive capital.
Bristol Myers Squibb (NYSE: BMY) on Wednesday August 26, 2026 ended its cell therapy manufacturing alliance with Cellares (South San Francisco) after finding that Cellares' Cell Shuttle automated production system failed to meet the requirements for making the CAR-T immunotherapy Breyanzi (lisocabtagene maraleucel). BMS and Cellares had signed a $380 million global capacity reservation and supply agreement in 2024 that positioned BMS to use Cell Shuttle for end-to-end automated CAR-T production at clinical and commercial scales. Cellares announced 100 layoffs (roughly 20% of the workforce) in response to the loss of the contract, coming just two months after closing a $327 million Series D. Cellares CEO Fabian Gerlinghaus said the company will 'resize' operations. The story is a data point on the fragility of contract cell-therapy manufacturing platforms and, by extension, a caution flag on the parallel automated-peptide-synthesis vendor category as GLP-1 and next-gen peptide production leans further on continuous-flow and automated platforms.
Pfizer (NYSE: PFE) in its Q2 2026 quarterly clearout discontinued clinical development of MET-224o, an oral fully-biased ultra-long-acting GLP-1 receptor agonist in Phase 1 for chronic weight management that came over in the $10 billion Metsera acquisition completed November 2025. MET-224o was developed by D&D Pharmatech (KOSDAQ: 259540) using its ORALINK oral peptide delivery platform. D&D Pharmatech stated the discontinuation was a strategic decision by Pfizer to focus on differentiated products as a late entrant in the oral obesity market rather than a technical issue with the platform. With MET-224o out, Pfizer's oral obesity pipeline collapses to a single asset: PF-08642534 (Pfizer's name for YP05002). The pruning continues Pfizer's pattern of aggressive Metsera-portfolio triage (a GIPR prospect was also dropped in the same clearout) and narrows an already-crowded oral GLP-1 field where Lilly's Foundayo (orforglipron) and Novo's Wegovy pill (oral semaglutide 25 mg) are already commercial.
Samsung Biologics' $1.8 billion (CHF 1.46 billion) all-cash tender offer for Swiss peptide CDMO PolyPeptide Group (SIX: PPGN) is scheduled to publish the formal offer prospectus by the end of August 2026, following the mandatory 10 trading-day cooling-off period under Swiss takeover law. Terms: CHF 44.31 per share (40% premium to the CHF 31.65 undisturbed price on April 10, 2026). The offer will run for a minimum of 20 trading days on SIX Swiss Exchange and is conditioned on at least 66⅔% of shares tendered on a fully diluted basis plus customary regulatory approvals. Deal close is targeted for end of 2026, after which Samsung intends to squeeze out remaining minorities and delist PolyPeptide. The transaction would give Samsung Biologics one of the top three peptide CDMO capacity positions globally, integrated with Samsung's existing multi-modality biologics network across the U.S., Europe, and India.
Eisai (TSE: 4523) and Biogen (NASDAQ: BIIB) announced Wednesday August 26, 2026 that once-weekly subcutaneous lecanemab-irmb (brand name Leqembi Iqlik) is now commercially available in the United States for initiation therapy in adults with early Alzheimer's disease (AD). Approved patient population: adults with mild cognitive impairment (MCI) or mild dementia due to AD, the same patient population that was approved for the IV formulation. Mechanism: lecanemab is a humanized IgG1 monoclonal antibody targeting soluble amyloid-beta protofibrils and preventing their aggregation into amyloid plaques that drive Alzheimer's pathology. Delivery format shift: the US launch represents the anti-amyloid class's substantive transition from the existing twice-monthly IV infusion format (requiring 1 hour of infusion time plus monitoring) to a weekly subcutaneous injection that substantially improves patient accessibility and reduces the infrastructure burden that has constrained the ongoing global Leqembi launch. Practical impact on Leqembi commercial trajectory: the SC format removes several barriers including infusion center scheduling constraints, long chair time per dose, and IV line placement complications. Eisai and Biogen have been struggling with slower-than-expected Leqembi launch since initial 2023 FDA approval due to reimbursement complexity, MRI monitoring requirements for amyloid-related imaging abnormalities (ARIA), and infrastructure requirements; the SC availability addresses one substantive barrier. Q2 2026 Leqembi worldwide sales reached roughly $340 million; the SC transition is expected to accelerate the commercial trajectory in Q4 2026 and into 2027.
BioMarin Pharmaceutical (NASDAQ: BMRN) disclosed Wednesday August 26, 2026 additional detail on the previously-announced Alesta Therapeutics acquisition (definitive agreement announced August 21). Transaction value: $275 million. Alesta's lead asset ALE1: an oral hypophosphatasia (HPP) therapy in clinical development. Hypophosphatasia is a rare inherited metabolic disease caused by loss-of-function mutations in the ALPL gene encoding tissue-nonspecific alkaline phosphatase (TNSALP), an enzyme required for bone mineralization and other biological processes; without adequate TNSALP activity, patients develop rickets, osteomalacia, seizures (in the severe perinatal form), and other complications. Commercial context: the currently-approved treatment is AstraZeneca / Alexion's Strensiq (asfotase alfa), a recombinant TNSALP-Fc fusion protein administered as three-times-weekly subcutaneous injection at a list price of approximately $1.5-2.0 million per adult patient per year. ALE1 would compete as a smaller-molecule oral format that could expand access to adult HPP patients where the injectable enzyme replacement has been less-broadly reimbursed by payers due to cost and administration burden concerns. The acquisition continues BioMarin's rare-disease portfolio expansion following the Amicus Therapeutics integration earlier in 2026 (which added GALAFOLD for Fabry disease and POMBILITI + OPFOLDA for late-onset Pompe disease) alongside Voxzogo (vosoritide, C-type natriuretic peptide analog for achondroplasia, on track for $1+ billion annual sales in 2026) and the broader enzyme-replacement franchise.
Chinese innovative drug developer Haisco Pharmaceutical Group (SHE: 002653) entered Wednesday August 26, 2026 an exclusive licensing agreement with Sentivera, a newly formed US venture backed by Population Health Partners and ARCH Venture Partners. Financial terms and specific asset details for the Haisco-Sentivera agreement have not been fully publicly disclosed in initial press coverage; additional detail is expected in the deal filing documents. The transaction extends the growing Chinese biotech pattern of ex-China commercialization partnerships that has substantially accelerated across 2025 and 2026. Recent comparable transactions include: Hengrui Pharma to Kailera Therapeutics for ribupatide (once-weekly injectable GLP-1/GIP/glucagon triple agonist peptide, with Kailera's US Phase 3 planned H1 2027); Hanmi Pharm to Genentech for HM17321 (urocortin-2 analog peptide for obesity via CRFR2 receptor, $190 million upfront + up to $2.3 billion in milestones + tiered royalties, announced August 24); Innovent Biologics' IBI3032 receiving FDA IND clearance August 5 and multiple additional Chinese CDE implied licenses August 18 for synchronized dual-region development; and Minwei Bio's MWN105 Phase Ib registration August 19-20 targeting semaglutide-intolerant populations. The pattern reflects the increasing sophistication of Chinese biotech clinical strategy targeting global markets rather than China-only launches, and it also reflects US venture capital interest in accessing Chinese-originated clinical-stage assets at attractive valuations relative to comparable US biotech candidates.
Sell-side analysts published Tuesday August 25, 2026 projections that Merck (NYSE: MRK) and Moderna (NASDAQ: MRNA) intismeran autogene (V940 / mRNA-4157) will exceed $1 billion in annual sales by 2031 following the August 19 positive Phase 3 INTerpath-001 melanoma readout. Product context: intismeran autogene is an individualized neoantigen therapy that uses each individual patient's tumor mutation signature to design a personalized mRNA vaccine encoding up to 34 tumor-specific neoantigen peptides. The mRNA is delivered as a lipid nanoparticle injection; cells at the injection site translate the mRNA into the neoantigen peptides, which are then presented to the immune system to generate a targeted T-cell response against the patient's tumor. The INTerpath-001 Phase 3 trial met its primary endpoint of recurrence-free survival and key secondary endpoint of distant metastasis-free survival in adults with completely resected Stage IIB-IV cutaneous melanoma. The $1+ billion 2031 sales trajectory assumes approvals across additional adjuvant indications currently in Phase 3 development including non-small-cell lung cancer (INTerpath-002), renal cell carcinoma (INTerpath-003), and cutaneous squamous cell carcinoma (INTerpath-005). Manufacturing scale-up remains a substantial commercial constraint because each patient dose requires an individualized manufacturing run driven by that patient's tumor sequence, unlike traditional off-the-shelf drugs; Moderna is investing in automated manufacturing infrastructure to support the projected launch volumes. The sales trajectory reset materially resets investor expectations about the personalized neoantigen therapy modality that had traded largely on Phase 2 data until the August 19 confirmatory Phase 3 result.
Follow-through analyst commentary Tuesday August 25, 2026 on the Monday Roche (SIX: ROG) and Hanmi Pharm HM17321 urocortin-2 (UCN2) obesity licensing deal positioned Roche as now targeting a top-three global obesity commercial position behind Eli Lilly (Zepbound, Mounjaro, Foundayo, and upcoming retatrutide) and Novo Nordisk (Wegovy, Ozempic, Wegovy Pill, Wegovy HD, CagriSema under review). Deal recap: $190 million upfront, up to $2.3 billion in milestones, plus tiered royalties; Genentech gets global rights excluding South Korea. HM17321 mechanism: a proprietary urocortin-2 (UCN2) analog peptide that selectively activates the corticotropin-releasing factor 2 receptor (CRFR2), a mechanism distinct from the incretin pathway (GLP-1, GIP) that anchors every currently-approved obesity drug. Roche obesity portfolio positioning: HM17321 combines with Roche's existing CT-388 (a dual GIP/GLP-1 receptor agonist acquired in the December 2023 Carmot Therapeutics acquisition for $2.7 billion, currently in Phase 2 for obesity and type 2 diabetes) and the emerging Roche obesity pipeline including RG7500 orforglipron precursor and other early-stage assets. The multi-mechanism portfolio provides a differentiated commercial positioning to compete across weight-loss efficacy (Roche's incretin agonist candidates match Lilly and Novo) and muscle-preservation (HM17321's differentiated UCN2 mechanism designed for lean mass preservation). Roche's obesity ambition contrasts with prior investor skepticism about its late-cycle entry into the category; Tuesday's analyst commentary suggests the multi-mechanism strategy could position Roche credibly for 2028-2030 commercial launches assuming pipeline programs advance to registration.
Hanmi Pharm (KRX: 128940) signed Monday August 24, 2026 an exclusive licensing agreement with Genentech (a member of the Roche Group) for HM17321, a proprietary urocortin-2 (UCN2) analog peptide for obesity. Deal terms: $190 million upfront payment, up to $2.3 billion in development, regulatory, and commercial milestone payments, plus tiered royalties on sales. Territory: Genentech secures global rights excluding South Korea, where Hanmi retains the license. Mechanism: HM17321 selectively activates the corticotropin-releasing factor 2 receptor (CRFR2), a peptide-hormone receptor pathway distinct from the incretin pathway (GLP-1 receptor, GIP receptor) that anchors every currently-approved obesity drug including semaglutide, tirzepatide, orforglipron, and the broader GLP-1 receptor agonist class. Urocortin-2 is a naturally occurring 38-amino-acid peptide of the corticotropin-releasing factor family. Differentiated profile: HM17321 is positioned as a potential first-in-class treatment designed to simultaneously promote weight loss and preserve lean body mass, an important differentiator against the semaglutide-tirzepatide-retatrutide GLP-1 class where roughly 25% of the total weight lost is lean muscle mass. Development pathway: Hanmi received FDA IND clearance to initiate a Phase 1 clinical trial in November 2025. Hanmi is responsible for completing the Phase 1 clinical trial, after which Genentech will take over development starting with Phase 2 clinical trials. The deal represents one of the largest 2026 obesity licensing transactions and adds a substantially different mechanism to Roche's obesity portfolio that also includes CT-388 (dual GIP/GLP-1 agonist from the Carmot Therapeutics acquisition).
Barclays' Head of US Biopharma Equity Research Emily Field told CNBC Monday August 24, 2026 that the biotech mergers and acquisitions (M&A) freeze is over. Key drivers cited: capital markets reopening (drug startup IPOs have raised roughly $6 billion year-to-date, more than the combined total of the prior four years by this point), large-cap pharma buyers committing to more deals following a multi-year period of caution, and fresh oncology data extending the sector's value proposition beyond the weight-loss drug narrative that dominated 2024-2025. The commentary follows a rapid acceleration of biotech M&A activity through August: Samsung Biologics' pending $1.8 billion PolyPeptide Group AG all-cash tender offer (formal prospectus expected end of August), BioMarin Pharmaceutical's Alesta Therapeutics acquisition for ALE1 program (August 21), Tolerance Bio's $260 million exclusive license from NeoImmuneTech for NT-I7 (efineptakin alfa, long-acting IL-7 fusion protein, August 20), LEO Pharma's dersimelagon (MC1R agonist) acquisition from Mitsubishi Tanabe (August 18), and Hanmi Pharm's up-to-$2.3 billion HM17321 UCN2 licensing to Genentech announced the same Monday. The pattern suggests the M&A environment is now supportive for both mid-cap platform buyers (Samsung Biologics, LEO Pharma, BioMarin) and mega-cap oncology and metabolic-disease buyers (Roche/Genentech, Bristol Myers Squibb, Merck, Eli Lilly) actively pursuing deals. Field's commentary also notes that oncology data (particularly the Merck-Moderna intismeran Phase 3 melanoma win and Gilead Trodelvy+Keytruda EU authorization from the same week) has substantially reset investor expectations about the sector beyond obesity.
WuXi Biologics (HKEX: 2269) announced Sunday August 23, 2026 an agreement to sell its 51.1% stake in Bestchrom, a Shanghai-based supplier of chromatography resins and columns used across peptide and biologic manufacturing, to an undisclosed independent third party. Financial terms of the transaction were not publicly disclosed. Bestchrom's chromatography resins and columns are used across peptide active pharmaceutical ingredient (API) downstream purification (removing impurities from crude peptide product after synthesis) and are part of the broader peptide-CDMO supply chain that supports the GLP-1 and rare-disease peptide manufacturing scale-up. The divestment continues WuXi's strategic portfolio pruning: the company sold its US manufacturing operations to Altaris Capital in January 2025 following the BIOSECURE Act pressures on Chinese biotech companies serving US customers, and sold its vaccine manufacturing business in December 2024. The Bestchrom divestment repositions WuXi around its core antibody, antibody-drug conjugate, and recombinant protein contract manufacturing services. For the broader peptide manufacturing landscape, the Bestchrom transaction adds another data point to the CDMO consolidation and specialization trend that also includes Samsung Biologics' pending $1.8 billion acquisition of PolyPeptide Group (prospectus expected end of August), the Gland Pharma / Neuland Laboratories sterile API partnership in Visakhapatnam, and ongoing capacity build-outs at Bachem, CordenPharma, and AmbioPharm.
BioMarin Pharmaceutical (NASDAQ: BMRN) announced Friday August 21, 2026 a definitive agreement to acquire Dutch biotech Alesta Therapeutics to gain Alesta's lead clinical-stage asset ALE1. Financial terms of the transaction were not publicly disclosed. Alesta's ALE1 program is in clinical development; the specific mechanism and indication have not been fully disclosed in initial press coverage, and additional details are expected in the deal filing documents. The acquisition adds to BioMarin's rare-disease portfolio alongside VOXZOGO (vosoritide, C-type natriuretic peptide analog administered as daily subcutaneous injection for achondroplasia in pediatric patients; delivered Q2 2026 revenue of $253 million +14% YoY and is on track for $1+ billion annual sales as BioMarin's first blockbuster franchise), the newly-integrated Amicus Therapeutics assets (GALAFOLD migalastat oral chaperone for Fabry disease, POMBILITI + OPFOLDA cipaglucosidase alfa plus miglustat for late-onset Pompe disease), and the broader enzyme-replacement franchise (VIMIZIM, Naglazyme, Aldurazyme, Palynziq). The Alesta acquisition continues BioMarin's pattern of rare-disease portfolio expansion following the Amicus integration completed earlier in 2026 that added roughly $220 million in expected non-GAAP cost synergies by 2028 and non-GAAP diluted EPS accretion beginning 2027. BioMarin's strategy of building a diversified rare-disease commercial franchise across peptide analogs (Voxzogo), oral small-molecule chaperones (GALAFOLD), enzyme replacements (Palynziq, VIMIZIM, Naglazyme, Aldurazyme), and now Alesta's ALE1 program continues to differentiate the company from single-franchise rare-disease competitors.
Chinese biotech peptide pipeline expanded across the week ending August 22, 2026. Key registrations and advances: Gan & Lee Pharmaceuticals initiated a Phase II clinical trial of GZR102 (a basal insulin plus GLP-1 receptor agonist fixed-dose weekly formulation) on August 8, targeting patients requiring both basal glycemic control and appetite-and-glucose modulation from a single weekly injection; Gan & Lee also registered a Phase I study of GZR18 on August 15. Xianweida registered XW003 (ecnoglutide) Phase I clinical trial for adolescent obesity on August 8, extending the ecnoglutide franchise into pediatric obesity development after the adult Phase 3 EECOH-2 win. Wayne Biotech WBD156 capsule (oral peptide candidate) advanced through preclinical/early-clinical development. Fujian Genorup's semaglutide pipeline expanded across multiple formulation and indication programs. The week's pattern extends the broader Chinese biotech GLP-1 pipeline expansion that now spans ribupatide (Hengrui-Kailera, once-weekly injectable GLP-1/GIP/glucagon triple agonist, global Phase 3 planned H1 2027), mazdutide (Innovent, GLP-1/glucagon dual agonist in late-stage Chinese and US trials), MWN105 (Minwei Bio, targeting semaglutide-intolerant populations), IBI3032 (Innovent, FDA IND clearance August 5), and multiple additional candidates. The synchronized China+US development pattern reflects the increasing sophistication of Chinese biotech clinical strategy targeting global markets rather than China-only launches.